{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-100470","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2026-08-25T10:01:24+00:00","discovered_at":"2026-08-25T10:05:00.646774+00:00","generated_at":"2026-08-25T10:05:07.445667+00:00","sec_items":["3.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3","bullets":["Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.","Scheme expected effective Sept 3, 2026; BRNS ADSs to halt trading before market open that day.","Court hearing for scheme set for Sept 1, 2026 at Royal Courts of Justice, London.","After close, Topco renamed Clywedog Therapeutics Holdings, Inc., trading as CLYD on Nasdaq.","Company to delist ADSs from Nasdaq and file Form 15 to suspend reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-100470","json":"https://secwatch.observer/filing/0001104659-26-100470.json","markdown":"https://secwatch.observer/filing/0001104659-26-100470.md","text":"https://secwatch.observer/filing/0001104659-26-100470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/0001104659-26-100470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/tm2623930d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T10:05:07.445667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}